Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients

Overview

Treatment Study to assess of safety and efficiency of conditioning with Plerixafor and G-CSF as additional agents for prevention of graft failure after transplantation in patients with chronic granulomatous disease

Full Title of Study: “A Clinical Trial of Plerixafor With G-CSF as Additional Agents in Conditioning Regimen for Prevention of Graft Failure in Patients With Chronic Granulomatous Disease”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 1, 2023

Detailed Description

Severe primary or secondary graft dysfunction is one of major problem in patients with Chronic granulomatous disease (CGD). In this study the hypothesis is that the use of plerixafor and G-CSF as additional agents in conditioning regimen would offers advantages. The effect is based on mobilizing bone marrow stem cells into the peripheral blood and blocking CXCR4 chemokine receptors to prevent stem cell homing. Thus, some have hypothesized that plerixafor and G-CSF make free stromal space of the bone marrow available for donor stem cell engraftment. Moreover, stem cell release probably leads to liberation of host stem cells from the anti-apoptotic effects of the BM stroma for the more powerful effect of chemotherapy. Thus, the purpose of this study is to evaluate the safety and efficiency of myeloablative conditioning with Plerixafor and G-CSF as additional agents for prevention of graft failure after stem cell transplantation in patients with chronic granulomatous disease.

Interventions

  • Drug: Plerixafor
    • Plerixafor for Conditioning before HSCT.
  • Drug: Gcsf
    • GCSF for Conditioning before HSCT.

Arms, Groups and Cohorts

  • Experimental: Plerixafor/G-CSF
    • Plerixafor/G-CSF for HSCT conditioning Myeloablative conditioning regimen with Plerixafor as addition agent before stem cell transplantation in CGD patients

Clinical Trial Outcome Measures

Primary Measures

  • Event free survival
    • Time Frame: 1 year
    • The EFS probability compared with historical control. We mean event as primary (non-engraftment) and secondary (rejection) graft dysfunction.

Secondary Measures

  • 1. Overall survival
    • Time Frame: 1 year
    • The OS probability compared with historical control
  • Proportion of patients with full/mixed donor chimerism
    • Time Frame: 30 days
    • Evaluation of the percentage of patients with the full/mixed donor chimerism (whole blood and CD3+ lineage). In addition, patients will be divided in accordance with % of donors cells: >95%; 50%-95%; 10%-49%; <10%. All data will be compared with historical control
  • 3. Transplant related mortality
    • Time Frame: 1 year
    • The TRM probability compared with historical control.
  • 4. Acute Graft Versus Host Diseases
    • Time Frame: 100 days
    • Cumulative Incidence of aGVHD
  • 5. Incidence of Plerixafor related toxicity
    • Time Frame: 100 days
    • severity, features, incidence

Participating in This Clinical Trial

Inclusion Criteria

Patients aged ≥ 1 months and < 25 years Patients diagnosed with CGD eligible for an allogeneic transplantation Signed written informed consent Exclusion Criteria:

Lack of informed consent.

Gender Eligibility: All

Minimum Age: 1 Month

Maximum Age: 24 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Federal Research Institute of Pediatric Hematology, Oncology and Immunology
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Dmitry Balashov, MD, +79265791817, bala8@yandex.ru

References

Balashov D, Laberko A, Shcherbina A, Trakhtman P, Abramov D, Gutovskaya E, Kozlovskaya S, Shelikhova L, Novichkova G, Maschan M, Rumiantsev A, Maschan A. A Conditioning Regimen with Plerixafor Is Safe and Improves the Outcome of TCRalphabeta+ and CD19+ Cell-Depleted Stem Cell Transplantation in Patients with Wiskott-Aldrich Syndrome. Biol Blood Marrow Transplant. 2018 Jul;24(7):1432-1440. doi: 10.1016/j.bbmt.2018.03.006. Epub 2018 Mar 14.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.